Pioneering in-hospital point-of-care manufacturing of cellular therapies worldwide

Blurred hospital corridor with healthcare staff and patient care rooms
Blurred hospital corridor with healthcare staff and patient care rooms
Logo

Pioneering in-hospital point-of-care manufacturing of cellular therapies worldwide

Cell manufacturing sites in academic medical centers

Commercially available cell therapies approved by the U.S. FDA are typically manufactured at the sponsoring pharmaceutical company’s centralized facilities.1 However, this model often presents logistical and cost-related challenges.2-4 For decades, some healthcare providers have implemented and expanded point-of-care (PoC) cell manufacturing within academic and clinical organizations enabling faster turnaround times due to the closer proximity to patients, reduced shipping complexity, and significant cost savings.5-8

The CliniMACS Prodigy® Platform enables PoC manufacturing of advanced therapies and is currently employed in hundreds of clinical trials and hospitals worldwide, underscoring its technical suitability for this application (see map below).

Below, we provide examples of leading cell manufacturing sites in academic hospitals at the forefront of implementing PoC manufacturing models in exploratory clinical trials, early access programs, or reimbursed hospital treatments. The affiliations listed correspond to the cell manufacturing sites responsible for producing the cellular products used in these clinical treatments.

Publications describing PoC manufacturing of cell therapies

Europe

Hospital Clínic de Barcelona and Hospital Sant Joan de Déu, Barcelona, Spain

  • Point-of-care CAR T therapies manufacturing: insights from nearly 500 productions by an academic institution
    Español-Rego, M. et al. Point-of-care CAR-T therapies manufacturing: insights from nearly 500 productions by an academic institution [poster]. EHA-EBMT 7th European CAR T-cell Meeting; 2025 May 15–17; Amsterdam, The Netherlands.

  • Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
    Fernandez De Larrea, C. et al. (2023) Lancet Oncol. 24: 913–924. | Read article

  • The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
    Martínez-Cibrián, N. et al. (2023) Br. J. Haematol. 204: 525–533. | Read article

  • CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies
    Ortíz-Maldonado, V. et al. (2021) Mol. Ther. 29: 636–644. | Read article

  • Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial
    Castella, M. et al. (2020) Front. Immunol. 11: 482. | Read article

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  • HSP-CAR30 with a high proportion of less differentiated T cells promotes durable responses in refractory CD30+ lymphoma
    Caballero, A. C. et al. (2025) Blood 145: 1788–1801. | Read article

La Paz University Hospital, Madrid, Spain

  • Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL
    González-Martínez, B. et al. (2025) EBioMedicine 118: 105872. | Read article

  • CD19 CAR T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease
    París-Muñoz, A. et al. (2025) Med. 6: 100676. | Read article

Bambino Gesù Children’s Hospital, Rome, Italy

  • Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse
    Del Bufalo, F. et al. (2025) Blood Adv. 9: 5091–5102. | Read article

  • Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis
    Nicolai, R. et al. (2024) Arthritis Rheumatol. 76: 1560–1565. | Read article

  • Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Locatelli, F. et al. (2024) Haematologica. 109: 1689–1699. | Read article

University Hospital Erlangen, Erlangen, Germany

  • CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis
    Krickau, T. et al. (2024) Lancet 403(10437): 1627–1630. | Read article

  • Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus
    Kretschmann, S. et al. (2023) Transplant Cell. Ther. 29: 27–33. | Read article

  • CD19-targeted CAR T cells in refractory systemic lupus erythematosus
    Mougiakakos, D. et al. (2021) N. Engl. J. Med. 385: 567–569. | Read article

University Hospital Tübingen, Tübingen, Germany

  • Allogeneic CD19/CD22 CAR T-cell therapy for B cell acute lymphoblastic leukemia
    Phely, L. et al. (2024) JAMA Oncol. 10: 821–824. | Read article

  • CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome
    Pecher, A-C. et al. (2023) JAMA Oncol. 329: 2154–2162. | Read article

  • Automated good manufacturing practice-compatible CRISPR-Cas9 editing of hematopoietic stem and progenitor cells for clinical treatment of β-hemoglobinopathies
    Ureña-Bailén, G. et al. (2023) CRISPR J. 6: 5–16. | Read article

University Hospital Heidelberg, Heidelberg, Germany

  • In vitro functionality and endurance of GMP-compliant point-of-care BCMA.CAR T cells at different timepoints of cryopreservation
    Jiang, G. et al. (2024) Int. J. Mol. Sci. 25: 1394. | Read article

  • Cost of decentralized CAR T-cell production in an academic nonprofit setting
    Ran, T. et al. (2020) Int. J. Cancer 147: 3438–3445. | Read article

Institute of Cellular Therapeutics (ICT), Hannover, Germany

  • Point-of-care anti-CD19-CAR T-cell therapy induces renal remission in refractory myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis
    Schultze-Florey, C. R. et al. (2025) Kidney Int. Rep. 10: 2491–2493. | Read article

  • Anti-CD19 CAR T cell therapy for acquired hemophilia A
    Schultze-Florey, C. R. et al. (2025) Leukemia 39: 980–982. | Read article

  • Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
    Aleksandrova, K. et al. (2024) Front. Immunol. 15: 1328368. | Read article

  • GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18
    Glienke, W. et al. (2022) Front. Immunol. 13: 839783. | Read article

Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

  • Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages
    Joedicke, J. J. et al. (2021) Mol. Ther. Methods Clin. Dev. 24:181–198. | Read article

Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Germany

  • Automated generation of gene-edited CAR T cells at clinical scale
    Alzubi, J. et al. (2020) Mol. Ther. Methods Clin. Dev. 20: 379–388. | Read article

German Red Cross Blood Service BaWü-He, Institute Frankfurt, Frankfurt, Germany

  • Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product
    Wiercinska, E. et al. (2023) J. Transl. Med. 21: 849. | Read article

Leiden University Medical Center, Leiden, The Netherlands

  • Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system
    Völzke, C. et al. (2024) Front. Immunol. 15: 1483254. | Read article

  • Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
    Yonezawa Ogusuku, I. E. et al. (2024) Mol. Ther. Methods Clin. Dev. 32: 101224. | Read article

Radboud University Medical Center, Nijmegen, The Netherlands

  • Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
    Bol, K. F. et al. (2024) Nat. Commun. 15: 1632. | Read article

University Hospital Brussels, Brussels, Belgium

  • Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
    Tijtgat, J. et al. (2024) J. Immunother. Cancer 12: e008148. | Read article

University College London, London, United Kingdom

  • Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B cell acute lymphoblastic leukemia
    Roddie, C. et al. (2021) J. Clin. Oncol. 39: 3352–3363. | Read article

  • Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy
    Mock, U. et al. (2016) Cytotherapy 18: 1002–1011. | Read article

Great Ormond Street Hospital for Children, London, United Kingdom

  • Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
    Ghorashian, S. et al. (2019) Nat. Med. 25: 1408–1414. | Read article

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

  • Place-of-care fresh formulation MB-CART19.1 cell products for clinical administration in a real-world setting
    Bukauskas, A. et al. EHA-EBMT 7th European CAR T-cell Meeting; 2025 May 15–17; Amsterdam, The Netherlands. | Read the poster

Finnish Red Cross Blood Service, Helsinki, Finland

  • Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts
    Farhana Jahan, F. et al. (2024) Sci. Rep. 14: 26678 | Read article

North and South America

British Columbia Cancer Research Institute, Victoria, BC, Canada

  • CLIC-01: Manufacture and distribution of non-cryopreserved CAR T cells for patients with CD19+ hematologic malignancies
    Kekre, N. et al. (2022) Front. Immunol. 13: 1074740. | Read article

University Hospitals Seidman Cancer Center in Cleveland, OH, and Siteman Cancer Center in St. Louis, MO, United States of America

  • Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
    Ghobadi, A. et al. (2025) EClinicalMedicine. 81: 103138. | Read article

Medical College of Wisconsin, Milwaukee, WI, United States of America

  • Phase I/II study of adaptive manufactured lentiviral antiCD20/anti-CD19 chimeric antigen receptor T cells for relapsed, refractory mantle cell lymphoma
    Shah, N. N. et al. (2025) J. Clin. Oncol. 43: 2285–2295. | Read article

  • Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device
    Zhu, F. et al. (2018) Cytotherapy 20: 394–406. | Read article

Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America

  • Chimeric antigen receptor T cell manufacturing on an automated cell processor
    Machietto, R. et al. (2023) J. Vis. Exp. 18: 198. | Read article

National Cancer Institute, National Institutes of Health, Bethesda, MD, United States of America

  • Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
    Dreyzin, A. et al. (2025) Cytotherapy. 101990. | Read article

  • CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
    Shalabi, H. et al. (2022) Blood 140: 451–463. | Read article

Weill Cornell Medicine, New York, NY, United States of America

  • Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
    Vedvyas, Y. et al. (2019) Sci. Rep. 9: 10634 | Read article

Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico

  • Decentralized point-of-care manufacturing of CD19 CAR T cells in Mexico
    Salazar-Riojas, R. et al. (2025) JCO Glob. Oncol. 11: e2400581. | Read article

Einstein Hospital Israelita, Sao Paulo, Brazil

  • Clinical validation of automated manufacture of autologous CD19 CAR T cells for treatment of B neoplasia
    Kerbauy, L. et al. (2022) Blood 140: 4930. | Read article

  • Results of the first Latin American point of care manufactured, phase I anti-CD19 CAR T study (CARTHIAE) for relapsed/refractory B cell neoplasms
    Kerbauy, L. et al. (2025) Blood 146: 2405. | Read article

Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, Brazil

  • Safety and efficacy of a new academic CD19-directed CAR T cell for R/R non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil
    Donadel, C. D. et al. (2024) Bone Marrow Transplant. 59: 1040–1042. | Read article

Asia and the Middle East

Christian Medical College, Vellore, Tamil Nadu, India

  • Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR T cell therapy in India: VELCART trial
    Palani, H. K. et al. (2025) Mol. Ther. Oncol. 33: 200977. | Read article

  • Decentralized manufacturing of anti-CD19 CAR T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India
    Palani, H. K. et al. (2023) Bone Marrow Transplant. 58: 160–167. | Read article

Seoul National University Hospital, Seoul, South Korea

  • Tagmentation-based analysis reveals the clonal behavior of CAR T cells in association with lentivector integration sites
    Kim, J. et al. (2023) Mol. Ther. Oncolytics. 30: 1–13. | Read article

Siriraj Hospital, Mahidol University, Bangkok, Thailand

  • Point-of-care manufacturing of anti-CD19 CAR T cells using a closed production platform: experiences of an academic in Thailand
    Luanpitpong, S. et al. (2024) Mol. Ther. Oncol. 32: 200889. | Read article

KK Women’s and Children’s Hospital, Singapore, Singapore

  • Manufacturing characteristics and early outcomes of a tandem aCD22-aCD19 CAR T therapy for childhood and adult relapsed/refractory acute precursor B lymphoblastic leukemia
    Seng, M. S-F. et al. Manufacturing Characteristics and Early Outcomes of a Tandem aCD22-aCD19 CAR-T Therapy for Childhood and Adult Relapsed/Refractory Acute Precursor B Lymphoblastic Leukemia [poster]. Tandem Meetings of ASTCT and CIBMTR; 2025 Feb 19–23; Orlando, FL, USA. | Read the poster

National Center for Biotechnology, Astana, Kazakhstan

  • Introducing CAR T therapy in Kazakhstan: establishing academic-scale lentiviral vector and CAR T cell production
    Keyer, V. et al. (2025) Biomolecules 15: 1166. | Read article

King Faisal Hospital, Riyadh, Saudi Arabia

  • Large scale in-house point-of-care manufacturing of clinical grade autologous anti-CD19 CAR T cells in Saudi Arabia
    Warda, W. et al. (2024) medRxiv. 24308741. | Read article

Dmitry Rogachev National Medical Research Center, Moscow, Russia

  • Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration
    Malakhova, E. et al. (2024) Cytotherapy 26: 567–578. | Read article

  • Multiple site place-of-care manufactured anti-CD19 CAR T cells induce high remission rates in B cell malignancy patients
    Maschan, M. et al. (2021) Nat. Commun. 12: 7200. | Read article

Reviews/position papers on PoC and patient access to cell and gene therapies

  • Establishing a sustainable academic point-of-care network for CAR T cell therapy
    Olesti, E. et al. (2025) Blood Advances Lancet Haematol. 12: e774–776. | Read article

  • Point-of-care CAR T cell therapy: toward broader access
    Rives, S. (2025) Blood Adv. 9: 5103–5104. | Read article

  • Surveying local CAR T cell manufacturing processes to facilitate standardization and expand accessibility
    Gupta, D. and Shaz, B. (2025) J. Transl. Med. 23: 507. | Read article

  • Harmonisation of quality control tests for academic production of CAR T cells: a position paper from WP-bioproduction of the UNITC consortium
    Marton, C. et al. (2025) Bone Marrow Transplant. 60: 1209–1217. | Read article

  • Manufacturing NK cells for the clinic: the Spanish experience
    Pérez-Martínez, A. et al. (2002) Cell & Gene Therapy Insights 8: 1539–1549. | Read article

  • The translational gap for gene therapies in low- and middle- income countries
    Doxzen, K. W. et al. (2024) Sci. Transl. Med. 16. | Read article

  • Point-of-care CAR T manufacturing solutions: can 1 model fit all?
    Urbano-Ispizua, Á. et al. (2024) Blood Adv. 8: 6133–6136. | Read article

  • Enhancing pediatric access to cell and gene therapies
    Mackall, C. L. et al. (2024) Nat. Med. 30:1836–1846. | Read article

  • The development of academic CAR T cells
    Delgado J. et al. (2024) Lancet Haematol. 11: e484–485. | Read article

  • Chimeric antigen receptor (CAR) T cell products for pediatric cancers: why alternative development paths are needed
    Rössig, C. et al. (2024) J. Clin. Oncol. 42: 253–257. | Read article

  • Cost of implementing CAR T activity and managing CAR T patients: an exploratory study
    Cavallo, M. C. et al. (2024) BMC Health Serv Res. 24: 121. | Read article

  • Expanding access to CAR T cell therapies through local manufacturing
    Elsallab, M. and Maus, M.V. (2023) Nat. Biotechnol. 41: 1698–1708.| Read article

  • Promises and challenges of a decentralized CAR T cell manufacturing model
    Shah, M. et al. (2023) Front Transplant. 2: 1238535. | Read article

  • Place of care manufacturing of chimeric antigen receptor cells: opportunities and challenges
    Orentas, R. J. et al. (2023) Semin. Hematol. 60: 20–24. | Read article

  • Role of hospital exemption in europe: position paper from the Spanish Advanced Therapy Network (TERAV)
    Sánchez-Guijo, F. et al. (2023) Bone Marrow Transplant. 58: 727–728. | Read article

  • Should we adopt an automated de-centralized model of chimeric antigen receptor T cells manufacturing for low-and middle-income countries? A real world perspective.
    Ramarishnan, S. et al. (2022) Front. Oncol. 12: 1062296. | Read article

  • Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
    Martinez-Cibrian, N. et al. (2022) Front. Immunol. 13: 1005457. | Read article

  • Cost of decentralized CAR T-cell production in an academic nonprofit setting
    Ran, T. et al. (2020) Int. J. Cancer 147: 3438–3445. | Read article

  • Eight-day point of care CAR T-cell manufacturing on Clinimacs Prodigy from healthy donors as a proof-of-concept study
    Hankey, K. G. et al. (2021) Blood 138: 285. | Read article

Regulation and guidelines for the manufacturing of cellular products

  • EudraLex, Volume 4, Part IV, GMP requirements for Advanced Therapy Medicinal Products (ATMPs) | Read regulation

  • Manufacture of Advanced Therapy Medicinal Products for human use. PIC/S GMP guide PE 009-15 with annex 2A – ATMPs | Read regulation

  • Considerations for the development of chimeric antigen receptor (CAR) T Cell products. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, January 2024 | Read guidance

  • The Human Medicines (Amendment) (Modular manufacture and point of care). Regulations 2025. 2025 No. 87 MEDICINES (The Secretary of State in relation to England and Wales and Scotland, and The Department of Health in Northern Ireland) | Read regulation

  • Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. European Medicines Agency, Committee for Advanced Therapies (CAT)/22473/2025 20 January 2025 | Read guideline

  • Optimizing CAR T treatment: A T2EVOLVE guide to raw and starting material selection
    Navarro, S. et al. (2025) Mol. Ther. 33: 847–865. | Read article

Regulation and guidelines for patient treatment
with non-commerical cell therapies


European Union

  • Hospital exemption clauses:
    • Regulation (EC) No 1394/2007 of the European Parliament and of the Council on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004 13 November 2007 | Read regulation
    • Advanced Therapy Medicinal Products (ATMPs): recommendations for good practice Europe | Read more

  • The Spanish Agency for Medicines and Health Products (AEMPS)
    • Authorizing the CAR T ARI-0001 from Hospital Clinic for patients with acute lymphoblastic leukemia | Read report

  • Study on the hospital exemption from the European Commission final report | Read report
    • Annex 1: country-specific information on how 19 EU member states interpreted and implemented the Hospital Exemption (HE) clause | Read annex
    • Annex 2: country-specific insights into regulatory pathways similar to the hospital exemption (HE) for advanced therapies in some non-EU jurisdictions | Read annex

  • Compassionate use
    • Recommendations from the Heads of Medicines Agencies (HMA) | Read guidance


United Kingdom

  • GOV UK, medicines & healthcare products, regulatory agency
    • Human medicines, modular manufacture and point of care regulations 2025: Overview | Read guidance


United States of America

  • CDER, U.S. FDA
    • 2022 Distributed manufacturing and point-of-care manufacturing of drugs | Read article